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Epidermal growth factor receptor (EGFR) mutations are a potential predictor of the effectiveness of EGFR inhibitors for the
treatment of lung cancer. Although EGFR mutations were reported to occur with high frequency in nonsmoking Japanese
adenocarcinoma patients, the exact nature has not been fully elucidated. We examined EGFR gene mutations within exons 18–21
and their correlations to clinico-pathological factors and other genetic alterations in tumour specimens from 154 patients who
underwent resection for lung cancer at Kyoto University Hospital. Epidermal growth factor receptor mutations were observed in 60
tumours (39.0%), all of which were adenocarcinoma. Among the patients with adenocarcinoma (n¼108), EGFR mutations were
more frequently observed in nonsmokers than former smokers or current smokers (83.0, 50.0, 15.2%, respectively), in women than
men (76.3 vs 34.0%), in tumours with bronchio-alveolar component than those without bronchio-alveolar component (78.9 vs
42.9%), and in well or moderately differentiated tumours than poorly differentiated tumours (72.0, 64.4, 34.2%). No tumours with
EGFR mutations had any K-ras codon 12 mutations, which were well-known smoking-related gene mutations. In conclusion,
adenocarcinomas with EGFR mutation had a distinctive clinico-pathological feature unrelated to smoking. Epidermal growth factor
receptor mutations may play a key role in the development of smoking-independent adenocarcinoma.
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Lung cancer is the leading cause of cancer death in many
industrialised countries. Cigarette smoking is the most important
cause of lung cancer, and a number of smoking-related gene
alternations have been identified that are responsible for the
development of lung cancer, such as mutations in K-ras (Vineis
and Caporaso, 1995; Shields, 2002). However, lung cancer also
develops in nonsmokers, and 30–40% of the lung cancer patients
in Japan have never smoked history are female, and their major
histological tumour type is adenocarcinoma (Sobue et al, 1994;
Akazawa et al, 2003). While several reports have shown that the
adenocarcinomas that occurred in nonsmokers were distinct
from those that developed in smokers in terms of their histological
subclassification, prognosis, gene expression pattern, and gene
alterations (Tsuchiya et al, 1988; Hashimoto et al, 2000; Ahrendt
et al, 2001; Bhattacharjee et al, 2001; Koga et al, 2001; Noda et al,
2001; Vahakangas et al, 2001; Yang et al, 2002), few significant
genetic alterations have been reported in adenocarcinomas that
developed in nonsmokers.
Recent laboratory studies have shown that the epidermal growth
factor receptor (EGFR, also known as ErbB1 or HER1) plays a
critical role in the development and progression of a variety of
malignant tumours by promoting cell growth, and by preventing
apoptosis through regulation of downstream effectors such as
mitogen-activated protein kinase, protein kinase B, and signal
transducer and activator of transcription 3 (Klapper et al, 2000). It
has been shown in clinical studies that EGFR is overexpressed in
40–80% of non-small-cell lung carcinomas (NSCLCs) (Bunn and
Franklin, 2002), and in preneoplastic lesions (Flanklin et al, 2002).
These findings suggest that EGFR might have the potential to be an
important molecular target for the diagnosis and treatment of
NSCLC. However, it is important to note that the exact role of
measuring EGFR status in clinical setting remains unclear: EGFR
expression status may not be useful as a prognostic tool (Meert
et al, 2002), and may not predict responsiveness to treatment with
gefitinib, a small-molecule EGFR tyrosine kinase inhibitor (Kris
et al, 2003).
Lynch et al (2004) and Paez et al (2004) recently identified
specific mutations in the tyrosine kinase domain of the EGFR gene
within exons 18, 19, and 21 in most NSCLC patients who
responded to gefitinib. Furthermore, Pao et al (2004) reported
the presence of a point mutation in exon 20 of the EGFR gene in an
adenocarcinoma patient who responded to erlotinib, another
EGFR tyrosine kinase inhibitor. Lynch et al (2004) and Pao et al
(2004) also showed that cancer cells transfected with EGFR gene
mutations showed enhanced tyrosine kinase activity in response to
binding of epidermal growth factor and increased sensitivity to
gefitinib and erlotinib, suggesting that specific EGFR mutations
may predict responsiveness to this type of treatment.
On the other hand, Paez et al (2004) and Pao et al (2004)
reported that EGFR mutations were more frequent in female than
in male patients and in adenocarcinomas than in tumours of other
histological types. Moreover, reports objecting peoples in East Asia
(Huang et al, 2004; Kosaka et al, 2004; Shigematsu et al, 2005)
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mutations and the absence of smoking history, mainly seen in
female patients, were closely linked to EGFR mutations. These
reports are not only important in determining which patients
should receive EGFR-targeted treatment (Arteaga, 2004; Dancey,
2004) but also indicate that EGFR mutations may play a causal role
in the development of lung adenocarcinoma in nonsmokers.
To confirm the correlation of EGFR mutations with smoking, we
conducted a detailed study of EGFR gene mutations in NSCLC
patients who underwent tumour resection at a particular Japanese
hospital. In the study, mutations of p53 gene and K-ras gene codon
12, and promoter hypermethylation status of p16, RASSF1A, and
APC1A gene, were also examined because these gene alterations
had substantial role in pathogenesis of NSCLC and whether or not
they correlated to EGFR mutations could help to further clarify the
importance of EGFR mutations on pathogenesis of NSCLC. In
addition, we report the detection procedure of EGFR mutation
using polymerase chain reaction-single strand conformational
polymorphism (PCR–SSCP) method (Orita et al, 1989). As PCR–
SSCP method is very suitable for detecting mutations within a
relatively limited region such as EGFR gene mutations and has
been already used to detect p53 gene mutations commercially, the
method can be more easily applied to detect EGFR mutations in
clinical setting than direct sequence.
MATERIALS AND METHODS
Patients and data collection
A total of 154 consecutive patients with NSCLC who underwent
resection at the Department of Thoracic Surgery, Kyoto University
Hospital, from January 2003 to November 2004 were included in
the present study (Table 1). Clinical data of patients involved were
obtained from the inpatient and outpatient medical records, chest
X-ray films, whole-body computed tomography films, bone
scanning data, and operation records. On smoking status, we
classified patients into nonsmokers and smokers, and subclassified
smokers into former smoker (who stop smoking at least 6 months
before the time diagnosis of NSCLC) and current smoker. In total,
142 patients underwent complete lobe or segment in which the
tumour existed and also received hilar and mediastinal lymphnode
dissections. A total of 13 patients received partial lung resection
and lymphnode sampling. No patient was exposed to gefitinib
before his or her tumour was resected. Pathological staging was
determined using the current tumour-node-metastasis classifica-
tion system (UICC, 1997). The histological type and differentiation
grade of the tumours in these patients were determined using the.
Pathological diagnosis were performed by two pathologists,
unaware of the genetic information, of Kyoto University Hospital
Laboratory of Anatomic Pathology, and finally confirmed by one
pathologist (TM) according to the WHO classification system
(Travis et al, 1999). Many of adenocarcinomas were classified into
mixed subtype according to WHO classification system. Thus, to
clarify the impact of EGFR gene mutations on subtypes of
adenocarcinoma, classification according to the presence or
absence of each component (BAC, papillary, acinar, and solid
carcinoma with mucin (solid)) in a tumour was also employed in
this study. A written informed consent to perform genetic analyses
was obtained from all patients before surgery, and the study itself
was approved by the Ethics Committee of Kyoto University
Graduate School and Faculty of Medicine.
Tumour sample collection
Tumour tissues were frozen immediately after resection, and were
stored at  801C until DNA extraction. A part of each tumour tissue
was used for formalin-fixed, paraffin-embedded tissue block to
confirm that tumour cells were sufficiently included within the
sample. Genomic DNA was extracted using the FastDNA
s Kit
(Qbiogene Inc., USA) as recommended by the manufacturer. As
EGFR mutations were reported to be somatic, corresponding
nonmalignant lung tissues were analysed in only six cases
harbouring EGFR mutations in their tumour tissues, and all had
no EGFR mutations in their nonmalignant lung tissues.
Mutation detection and nucleotide sequence analysis of the
EGFR and p53 genes
Polymerase chain reaction-single strand conformational poly-
morphism (Orita et al, 1989) was used to screen for mutations in
the EGFR gene within exons 18–21 and for mutations in the p53
gene within exons 5–8. Polymerase chain reaction amplification
was performed using the HotStarTaq Master Mix (Qiagen,
Germany); the primers used and PCR conditions are listed in
Table 2. Single-strand conformational polymorphism analyses
were performed using the GenePhor System and GeneGel Excel
12.5/24 (Amersham Biosciences, Sweden) following the manufac-
turer’s protocol; the gel temperature was maintained at 101C for
SSCP analysis of exon 21 of the EGFR gene and exon 6 of the p53
gene, 151C for exons 18, 19, and 20 of the EGFR gene, and 181C for
exons 5, 7, and 8 of the p53 gene. After the gels were stained with
silver carbonate, altered bands were cut from the gels and DNA
fragments were eluted for direct sequencing. Each mutation within
exon 19 of the EGFR gene was expediently named according to the
start point of the amino-acid change and its order of detection, as
shown in Table 3.
Table 1 Characteristics of 154 patients included in the study
Patients characteristics
Age (year)
Median (range) 68 (31–83)
Gender (no.)
Female (%) 60 (39.0%)
Male (%) 94 (61.0%)
Smoking status (no.)
Non smoker (%) 56 (36.4%)
Smoker (%) 98 (63.6%)
Former 29
Current 69
Pack-year of smokers (pack-year)
All smokers
Median (range) 48 (2–250)
Former
Median (range) 30 (2–105)
Current
Median (range) 51 (6–250)
Tumour histology (no.)
Adenocarcinoma 108 (70.1%)
Squamous cell 31 (20.1%)
Large cell 9 (5.9%)
Other histologies 6 (3.9%)
Pathological stage (no.)
IA 63 (41.3%)
IB 38 (24.5%)
IIA 4 (2.6%)
IIB 11 (7.1%)
IIIA 26 (16.8%)
IIIB 10 (6.4%)
IV 2 (1.3%)
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Gene Forward (5’–3’) Reverse (50–30)
Product
size (bp)
Number
of cycle
Annealing
condition
EGFR
Exon 18 TACACCCAGTGGAGAAGCTCC CCCCACCAGACCATGAGAG 169 30 581C, 30s
Exon 19 CAATTGCCAGTTAACGTCTTCC GGAGATGAGCAGGGTCTAGAG 239 30 581C, 30s
Exon 20 CACACTGACGTGCCTCTC CTTATCTCCCCTCCCCGTA 252 30 561C, 30s
Exon 21 AGGGCATGAACTACTTG CCTCCTTACTTTGCCTCCTTC 167 35 551C, 30s
p53
Exon 5 TTCAACTCTGTCTCCTTCCT CAGCCCTGTCGTCTCTCCAG 248 30 551C, 30s
Exon 6 GCCTCTGATTCCTCACTGAT TTAACCCCTCCTCCCAGAGA 181 30 551C, 30s
Exon 7 CTTGCCACAGGTCTCCCCAA TGTGCAGGGTGGCAAGTGGC 196 30 591C, 30s
Exon 8 TTCCTTACTGCCTCTTGCTT CGCTTCTTGTCCTGCTTGCT 201 30 551C, 30s
K-ras ACTGAATATAAACTTGTGGTAGTTGGACCT CTGTATCAAAGAATGGTCCTGCACCAGTA 162 30 581C, 30s
p16
Unmethylated TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 151 35 601C, 30s
Methylated TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 150 35 651C, 15s
RASSF1A
Methylated GGGTTTTGCGAGAGCGCG GCTAACAAACGCGAACCG 169 35 641C, 50s
APC1A
Methylated TATTGCGGAGTGCGGGTC TCGACGAACTCCCGACGA 98 35 621C, 10s
Table 3 Types of EGFR gene mutations found in this study
Exon Type of sequence Alteration Nucleotide alteration Amino-acid alteration No. of cases
18 Substitution 2156G4C G719A 1
Substitution 2159C4T S720F 1
19 Type 1
1a Deletion 2235–2249delGGAATTAAGAGAAGC E746-A750del 14
1b Deletion 2236–2250delGAATTAAGAGAAGCA E746-A750del 8
1c Deletion+ 2235–2249delGGAATTAAGAGAAGC E746-A750del 1
Substitution 2251A4G T751A
1d Deletion+ 2235–2236delGC E746-A750del 1
Substitution 2242–2248delAGAGAAG ins I and P
2241A4C
1e Deletion 2235–2236delGC E746-T751del 2
2239–2252delTAAGAGAAGCAAC ins I
1f Deletion+ 2235–2236delGC E746-T751del 1
Substitution 2242–2251delAGAGAAGCAA ins I and P
2241A4C
1g Deletion+ 2237–2254delAATTAAGAGAAGCAACAT E746-S752del 1
Substitution 2255C4T ins V
Type 2
2a Deletion+ 2240–2248delTAAGAGAAG L747-A750 1
Substitution 2239T4C insP
2b Deletion+ 2240–2251delTAAGAGAAGCAA L747-T751del 2
Substitution 2239T4C ins S
2c Deletion 2239–2253delTTAAGAGAAGCAACA L747-T751del 1
2d Deletion 2239–2256delTTAAGAGAAGCAACATCT L747-S752del 1
2e Deletion 2240–2257delTAAGAGAAGCAACATCTC L747-P753del 1
ins S
20 Insertion+ 2308ins/dup(CCAGCGTGG) ins779(ASV) 1
Substitution 2310C4T, 2315C4G P782R
Insertion+ 2311ins/dup(GCGTGGACA) ins780(SVD) 1
Substitution 2315C4G P782R
21 Substitution 2573T4G L858R 20
Substitution 2572–2573CT4AG L858R 1
Substitution 2573–2574TG4GT L858R 1
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We used a modified mutagenic PCR–RFLP method (Hatzaki et al,
2001) for screening mutations in codon 12 of the K-ras gene. PCR
primers and the amplification conditions are shown in Table 2.
The PCR products of mutated K-ras genes were sequenced for
confirmation of mutation.
Promoter hypermethylation analysis
To detect promoter hypermethylation of the p16, RASSF1A, and
APC1A genes, methylation-specific PCR method was used (Herman
et al, 1996). PCR primers and the amplification conditions were listed
in Table 2 (Herman et al, 1996; Burbee et al, 2001; Yu et al, 2002).
Statistical analyses
The significance of differences in categorical data was tested using
the w
2 or Fisher’s exact test. Differences between continuous
variables were examined using the Mann–Whitney U-test. To
determine which of gender or smoking history, or which component
of subtype of adenocarcinoma affected EGFR mutations, logistic
regression analyses were performed. StatView software (version 5,
SAS Institute, USA) was used to carry out all statistical calculations.
All statistical tests were two-sided, and differences were considered
to be statistically significant if the P-value was less than 0.05.
RESULTS
Epidermal growth factor receptor mutations in non-small-
cell lung carcinomas
A total of 61 mutations in the EGFR gene were found in 60 of our
patients (39.0%). Mutations occurred within exon 18 in two
patients (1.3%), exon 19 in 34 patients (21.9%), exon 20 in three
patients (1.9%), and exon 21 in 22 patients (14.2%), respectively.
One patient had mutations within exon 19 and 20. Polymerase
chain reaction-single strand conformational polymorphism analysis
revealed two types of altered bands in exon 18 (Figure 1A), 12 types
in exon 19 (Figure 1B), three types in exon 20 (Figure 1C), and three
types in exon 21 (Figure 1D), and nucleotide sequencing confirmed
the presence of the corresponding mutations shown in Table 3. The
mutations identified within exon 18 were point mutation of
2156G4C( n¼1), which substituted alanine for glycine at codon
719, and point mutation of 2159C4T( n¼1), which substituted
phenylalanine for serine at codon 720 (Table 3). A total of 12 types
of mutations were discovered around codon 747–750 within exon
19, and 2235–2249del (n¼14) and 2236–2250del (n¼8) were
major types (Table 3). The mutations identified within exon 20 were
point mutation of 2361G4A and 2407C4A (silent mutation)
observed in one patient who had deletion mutation within exon 19,
and two types of duplication/insertion with point mutation
(Table 3). The mutations identified within exon 21 were point
mutation of 2573T4G( n¼20), 2572–2573CT4AG (n¼1), and
2573–2574TG4GT (n¼1). All these mutations provided amino-
acid substitution of arginine in the place of leucine at codon 858
(Table 3). Epidermal growth factor receptor mutations were
exclusively observed in adenocarcinoma patients; the incidence of
EGFR mutations in adenocarcinoma patients was 55.6% (60/108).
Other genetic alterations
In total, 52 mutations within exons 5–8 of the p53 gene were
observed in 51 patients (33.1%). The frequency distribution of
these mutations was as follows: 12 missense point mutations and
one duplication/insertion within exon 5; seven missense point
mutations, two deletions, and two duplication/insertion within
exon 6; four missense point mutations, three duplication/insertion,
and two deletions within exon 7; and 15 missense point mutations,
and four deletions within exon 8.
Mutations within codon 12 of the K-ras gene were observed in
10 patients (6.5%) with the following frequency: substitution of
cystein (TGT) in the place of glycine (n¼4), aspartic acid (GAT)
(n¼3), serine (AGT) (n¼1), valine (GTT) (n¼1), and phenyla-
lanine (TTT) (n¼1). All 10 patients with K-Ras mutated tumours
were smokers.
Promoter hypermethylation of p16, RASSF1A, or APC1A genes
was observed in 64 (41.6%), 78 (50.6%), or 82 (53.2%) of 154
patients, respectively.
Correlation of clinico-pathological characteristics and
other genetic alterations with EGFR mutations in lung
adenocarcinoma
As EGFR mutations were observed exclusively in adenocarcinoma
patients, we investigated the relationship between the clinical
W
W1 a1 b 1 c 1 d1 e1 f 1 g2 a2 b2 c 2 d 2 e
12
W1 2 3
W1 2 3
B
C
D
A
Figure 1 Single-strand conformation polymorphism of the EGFR gene.
Each band alteration corresponds to a specific gene mutation. (A) Exon 18.
W: wild type, 1: 2156G4C, 2: 2159C4T. Allow heads: altered bands. (B)
Exon 19. W: wild type. The designated types of mutation (1a–1g, 2a–2e)
in exon 19 were those described in Table 3. (C) Exon 20. W: wild type, 1:
2361G4A and 2407C4A, 2: 2308ins/dup(CCAGCGTGG) with
2310C4T and 2315C4G, 3: 2311ins/dup(GCGTGGACA) with
2315C4G. Allow heads: altered bands. (D) Exon 21. W: wild type, 1:
2573T4G, 2: 2573–2573CT4AG, 3: 2573–2574TG4GT. Allow heads:
altered bands.
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patients (n¼108) and their mutations (Table 4). The incidence of
EGFR mutations was higher in female patients than in male
patients (76.3 vs 34.0%, Po0.001, odds ratio: 6.3, 95% confidence
intervals: 2.7–14.7). The incidence of EGFR mutations was higher
in nonsmokers than in former smokers (83.0 vs 50.0%, P¼0.008,
odds ratio: 4.9, 95% confidence intervals: 1.5–15.7), and higher in
former smokers than in current smokers (50.0 vs 15.2%, P¼0.007,
odds ratio: 5.6, 95% confidence intervals: 1.4–21.7). There was a
significant correlation between gender and smoking status in these
patients; 48 of 53 male patients (90.6%) were smokers, whereas
only seven of 55 female patients (12.7%) were smokers (Po0.001,
odds ratio: 65.8, 95% confidence intervals: 23.3–186.1). Logistic
regression analysis revealed absence of smoking history, not
female, affected EGFR gene mutation (Po0.001, odds ratio: 11.4,
95% confidence intervals: 2.7–47.3).
Epidermal growth factor receptor mutations were more
frequently found in patients with lower pathologic stage
disease although there was no statistical significance (P¼0.059)
(Table 4).
The histological subtype of adenocarcinomas according to WHO
classification did not correlate statistically with their EGFR
incidence of mutations. Epidermal growth factor receptor muta-
tions were, however, more frequently observed in tumours with
BAC component than those without BAC component (78.9 vs
42.9%, Po0.001, odds ratio: 5.0, 95% confidence intervals:
2.0–12.6). By contraries, EGFR mutations were less frequently
observed in tumours with solid component than those without
solid component (34.2 vs 67.1%, P¼0.001, odds ratio: 0.25, 95%
confidence intervals: 0.11–0.61). Papillary component and acinar
component did not correlate to the incidence of EGFR gene
mutations (Table 4). Logistic regression analysis revealed that BAC
component positively related to EGFR gene mutations (P¼0.006,
odds ratio: 3.9, 95% confidence intervals: 1.5–10.1) and solid
component inversely related to EGFR gene mutations (P¼0.035,
odds ratio: 0.36, 95% confidence intervals: 0.14–0.93). The
differentiation grade of the tumours correlated significantly with
their incidence of EGFR mutations. Thus, incidence of EGFR
mutations was lower in poorly differentiated tumours than in well-
differentiated tumours (34.2 vs 72.0%, P¼0.005, odds ratio: 4.9,
95% confidence intervals: 1.5–15.9) or than in moderately
differentiated tumours (34.2 vs 64.4%, P¼0.008, odds ratio: 3.5,
95% confidence intervals: 1.3–9.2) (Table 4).
K-ras gene mutations were not detected in any of the EGFR
mutated tumours and this negative correlation was statistically
significant (P¼0.001), while EGFR gene mutation status did not
correlate with p53 gene mutation status or with promoter
hypermethylation status of p16, RASSF1A, or APC1A gene
(Table 4).
The detailed type of EGFR mutation did not correlate with
gender, smoking status, p-stage, histological subtype, grade of
tumour differentiation (data not shown).
DISCUSSION
In the present study, we detected EGFR gene mutations in 60
of 154 Japanese patients (39.0%) who underwent resection for
NSCLC. The demonstration of a high prevalence of these
mutations in our Japanese patients was consistent with previous
data that NSCLC occurred in people in the East Asia including
Japan showed higher prevalence of EGFR mutation (19–40%) than
those in other patient groups (4–10%) (Table 5). Our study clearly
showed that EGFR mutations were not only observed in advanced
NSCLC that may be considered for gefitinib treatment but also in
early NSCLC. This suggests that such mutations is involved in the
early stage of oncogenesis of NSCLC, so that EGFR mutations
should be investigated further in regard to oncogenesis of NSCLC,
as well as considered for design of clinical trial of or selecting
candidates of EGFR-targeting drugs.
A total of 15 base pair deletions within exon 19 and a point
mutation within exon 21 were two of the major types of mutations
that were found in our patients. Among 11 types of EGFR
mutations within exon 19, mutations of the type 1 series, in which
the start point for amino acid deletion was E746, were most
frequent. This finding was somewhat different from the findings in
US patients, in whom mutations that had their start point for
amino acid deletion at L747 were frequent (Lynch et al, 2004; Paez
et al, 2004), but was similar to those in other reports (Huang et al,
2004; Kosaka et al, 2004; Pao et al, 2004; Han et al, 2005; Marchetti
et al, 2005; Qin et al, 2005; Shigematsu et al, 2005; Yang et al,
2005). These differences may reflect ethnic and/or social differ-
ences among patient groups although the net effect of a deletion in
the type 1 or 2 series on sensitivity to EGFR tyrosine kinase
inhibitors seems similar (Huang et al, 2004; Lynch et al, 2004; Paez
et al, 2004; Pao et al, 2004; Han et al, 2005).
It is interesting that both mutations in exons 19 and 21 were
found with higher frequency (34/154 and 22/154, respectively) in
our patients than in patients outside of the East Asia (Table 5),
despite the type of each mutation were different (a deletion on
exon 19 and a point mutation on exon 21). This finding suggests
that one or just a few substances with DNA editing capacity may
mediate both deletions and point mutations within the tyrosine
kinase domain of the EGFR. Clarification of the mechanism by
which EGFR mutations occur can lead to advances in our
understanding of oncogenesis and its prevention.
Smoking history strongly affected the incidence of EGFR
mutations in our study. In addition to higher incidence of EGFR
mutations in adenocarcinomas developed in nonsmokers, we
showed that the incidence of EGFR mutations was higher in former
smokers than in current smokers. Former smokers had lower
pack-year (Table 1) and may be less affected by smoking. Probably
smoking is not involved in mechanisms of EGFR gene mutations.
Although the incidences of EGFR mutations were higher in
female patients and in nonsmokers, a history of smoking strongly
correlated with gender in our study. We showed that the absence of
smoking history, but not female, independently affected EGFR
gene mutations. This result is similar to the data of Kosaka et al
(2004), but is different from the data of Marchetti et al, which
indicated the absence of smoking history and female sex
independently influenced to EGFR mutations. This difference
may be derived from social difference on smoking between Japan
and Italy. At least, in NSCLC occurred in Japanese people, the
absence of smoking history, not female gender, seems a critical
factor that links to the prevalence of EGFR mutations.
We found that BAC component positively related to EGFR
mutations, solid component inversely related to EGFR gene
mutations, and that well-to-moderately differentiated adenocarci-
nomas had higher incidence of EGFR gene mutations than poorly
differentiated adenocarcinomas. These findings are consistent with
Lynch et al (2004), Kosaka et al (2004), and Marchetti et al (2005).
Adenocarcinomas that develop in nonsmokers frequently display
features of BAC and papillary type tumours, whereas those that
develop in smokers frequently include poorly differentiated and
solid subtype tumours (Hashimoto et al, 2000; Yang et al, 2002;
Nordquist et al, 2004). High incidence of harbouring EGFR
mutations in nonsmokers adenocarcinoma well-explains this
predilection on pathological findings. Thus, including BAC
component and well-to-moderate differentiation grade seem
histological features of adenocarcinomas with EGFR mutations.
K-ras mutations were not observed in any of the EGFR-mutated
tumours in our patients. This feature is similar to reports referring
EGFR mutations and K-ras mutations (Table 5). Both K-ras and
EGFR are important molecules that are responsible to the regu-
lation of the mitogen-activated protein kinase pathway. But K-ras
mutations are linked to the development of adenocarcinomas
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sTable 4 Relationship of EGFR gene mutations to clinicopathological characteristics and other genetic/epigenetic alterations in 108 patients with
adenocarcinoma
EGFR gene mutation status
Variable All patients Mutated(60) (%) Wild (48) P-value
Age (year)
Median (range) 67 (31–83) 66 (33–83) 68 (31–83) P¼0.256
Gender (no.)
Female 55 42 (76.3) 13 Po0.001
Male 53 18 (34.0) 35
Smoking history (no.)
Nonsmoker 53 44 (83.0) 9 P¼0.008
Former smoker 22 11 (50.0) 11
Current smoker 33 5 (15.2) 28 P¼0.007
Pathologic stage (no.)
I 71 45 (63.4) 26 P¼0.059
II 11 6 (54.5) 5
III 24 9 (37.5) 15
IV 2 0 (0) 2
Subtypes of adenocarcinoma (no.)
Bronchio-alveolar 3 2 (66.7) 1 P¼0.423
Papillary 19 10 (52.6) 9
Solid 2 0 (0) 2
Mixed 84 48 (57.1) 36
Acinar component (no.)
Present 77 41 (53.2) 36 P¼0.523
Absent 31 19 (61.3) 12
Bronchio-alveolar component (no.)
Present 38 30 (78.9) 8 Po0.001
Absent 70 30 (42.9) 40
Papillary component (no.)
Present 93 53 (57.0) 40 P¼0.578
Absent 15 7 (46.7) 8
Solid component (no.)
Present 38 13 (34.2) 25 P¼0.001
Absent 70 47 (67.1) 23
Tumour differentiation (no.)
Well 25 18 (72.0) 7 P¼0.005
Moderate 45 29 (64.4) 16
Poor 38 13 (34.2) 25 P¼0.008
p53 (no.)
Mutated 32 15 (46.9) 17 P¼0.291
Wild 76 45 (59.2) 31
K-ras codon 12 (no.)
Mutated 8 0 (0) 8 P¼0.001
Wild 100 60 (60.0) 40
p16 (no.)
Hypermethylated 44 20 (45.5) 24 P¼0.115
Unhypermethylated 64 40 (62.5) 24
RASSF1A (no.)
Hypermethylated 59 28 (47.5) 31 P¼0.081
Unhypermethylated 49 32 (65.3) 17
APC1A (no.)
Hypermethylated 66 38 (57.6) 28 P¼0.692
Unhypermethylated 42 22 (52.4) 20
j 


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sin smokers (Ahrendt et al, 2001), and are rarely observed in
adenocarcinomas in nonsmokers (Noda et al, 2001). This is in
marked contrast to EGFR mutations, which occur more frequently
in nonsmokers. Probably, EGFR mutations have a similar
significance to K-ras mutations in oncogenesis of lung adeno-
carcinomas. Unlike K-ras mutations involved in adenocarcinomas
developed in smokers, however, EGFR gene mutations may play a
key role in the development of adenocarcinomas in nonsmokers.
Similar to Kosaka et al (2004), EGFR mutations did not correlate
to p53 gene mutations in our study. Moreover, we showed that
EGFR mutations did not correlate to promoter hypermethylation
status of p16, RASSF1A, or APC1A genes. In the multistep
progression of sporadic colorectal carcinomas, K-ras mutations
are thought to occur independently at a different step from that of
p53 mutations (Klump et al, 2004). Similar situation is seen in K-
ras mutations, p53 mutations, and promoter hypermethylation of
p16 gene in pancreatic cancer (Moore et al, 2003). In NSCLC,
EGFR, p53, p16, RASSF1A, or APC1A can be involved in
oncogenesis at a different level from one another (Rom et al,
2000). Therefore, alterations of these genes can independently
occur in lung adenocarcinomas, unlike mutations of EGFR and
K-ras.
We used the PCR–SSCP method (Orita et al, 1989) to screen for
EGFR mutations. Advantages of the PCR–SSCP method are: it is
fast and easily employed for screening numerous samples
simultaneously, it indicates type-specific mutations without
nucleotide sequence because one altered SSCP-band pattern can
correspond to a specific mutation, and it has higher sensitivity
Table 5 Summary of previous reports on EGFR gene mutations in NSCLC
Patient No. of
Frequency in
Predilection
in non/
former
Histological
features in
Respose to
TKI
b of
patients with
EGFR
mutated Correlation Correlation
Reference group patients Overall Ad
a smokers Ad
a tumour to p53 to K-ras
Lynch et al
(2004)
USA 25
+16 TKI
b
receivers
2/25 2/22 Yes More frequent
in BAC
c
8 patients
in 9 responders
not in 7
nonresponders
——
Paez et al
(2004)
USA
Japan
119
+9
TKI
b
receivers
16/119
(13%)
1/61(2%)
in USA
15/58 (26%)
in Japan
15/70 (21%)
1/29(3%) in
USA
14/41(34%)
in Japan
Yes — 5 patients
in 5 responders
not in
nonresponders
——
Pao et al
(2004)
USA 96
+17 TKI
b
responders
11/96 (11%) — Yes — 12 patients
in 17 responders
——
Kosaka et al
(2004)
Japan 277 111/277
(40%)
110/224
(49%)
Yes More frequent
in well-to-
mederately
differentiated
Ad
a
— Independent Mutually
exclusive
Huang et al
(2004)
Taiwan 101 39/101
(39%)
38/69 (55%) Yes — 7 responders
in 9 patients
——
Marchetti
et al (2005)
Italy 860 37/860 (4%) 37/375
(10%)
Yes More frequent
in Ad with
BAC
c features
— — Mutually
exclusive
Han et al
(2005)
Korea 90 17/90 (19%) 14/65 (22%) No — 11 responders
in 17 patients
——
Shigematsu
et al (2005)
Japan
Taiwan
USA
Australia
519 120/519
(23%)
107/361
(30%)
in East Asia
13/158(8%)
in others
114/289
(39%)
102/214
(48%)
in East Asia
12/75(16%)
in others
Yes No correlation
to Ad with
BAC
c fearures
— — Mutually
exclusive
Qin et al
(2005)
China 41 10/41 (24%) 7/17 (41%) No — — — —
Yang et al
(2002)
USA 219 26/219
(12%)
25/164
(15%)
Yes — — — —
aAd¼adenocarcinoma.
bTKI¼tyrosine kinase inhibitor.
cBAC¼bronchio-alveolar carcinoma.
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sthan direct sequence sufficient for clinical use (Marchetti et al,
2005). The PCR–SSCP method can be theoretically applied not
only to resected tumour samples but also to sputum, pleural
effusion, and biopsy specimens; as such, this technique can be
used to preselect appropriate patients for EGFR tyrosine kinase
inhibitor treatment.
This study has several limitations. As only surgically resected
tumours were involved in the study, the incidence of EGFR
mutations in the study could not indicate the incidence in whole
NSCLCs. Mutations outside exons 18–21 were not examined, and
PCR–SSCP method has possibility to overlook mutations that is
not reflected on band pattern alterations, so that the incidence of
EGFR may be underestimated. The incidence of EGFR mutation
and types of mutations detected in our study are, however, quite
similar to previous reports; therefore, we think our study has
sufficient validity.
In conclusion, mutations in the EGFR gene were found in
approximately half of our Japanese adenocarcinoma patients, and
were more common in tumours developed in nonsmokers.
Adenocarcinomas with EGFR mutations displayed inclusion of
bronchio-alveolar component, or well-to-moderately differentiated
features, which are also one of the histological features of
adenocarcinomas in nonsmokers. Adenocarcinomas with EGFR
mutations negatively correlated with K-ras mutations that are
known to be associated with smoking. Thus, EGFR mutations may
play a role in the aetiology of adenocarcinoma in nonsmokers.
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